Motivation des patients à participer à un essai clinique de phase I en oncologie

Chaque année en Suisse, 15000 personnes meurent du cancer, ce qui en fait la deuxième cause de mortalité [1]. Il est donc nécessaire d'introduire sur le marché de nouveaux traitements plus efficaces. Ces derniers doivent passer par une période d'essais cliniques qui comporte plusieurs phases, dont la phase I. Celle-ci sert principalement à déterminer la dose maximale tolérable d'un médicament, en exposant le patient à des doses croissantes. Déterminer les motivations des patients à participer à la phase I d'un essai clinique, alors que les bénéfices personnels sont relativement faibles [3].

Genetic redox dysregulation induces behavioural deficits in the adult mouse: an animal model for schizophrenia

Background: Glutathione (GSH), a major cellular redox regulator and antioxidant, is decreased in cerebrospinal fluid and prefrontal cortex of schizophrenia patients. The gene of the key GSH-synthesizing enzyme, glutamate-cysteine ligase, modifier (GCLM) subunit, is associated with schizophrenia, suggesting that the deficit in the GSH system is of genetic origin. Using the GCLM knock-out (KO) mouse as model system with 60% decreased brain GSH levels and, thus, strong vulnerability to oxidative stress, we have shown that GSH dysregulation results in abnormal mouse brain morphology (e.g., reduced parvalbumin, PV, immuno-reactivity in frontal areas) and function. Additional oxidative stress, induced by GBR12909 (a dopamine re-uptake inhibitor), enhances morphological changes even further. Aim: In the present study we use the GCLM KO mouse model system, asking now, whether GSH dysregulation also compromises mouse behaviour and cognition. Methods: Male and female wildtype (WT) and GCLM-KO mice are treated with GBR12909 or phosphate buffered saline (PBS) from postnatal day (P) 5 to 10, and are behaviourally tested at P 60 and older. Results: In comparison to WT, KO animals of both sexes are hyperactive in the open field, display more frequent open arm entries on the elevated plus maze, longer float latencies in the Porsolt swim test, and more frequent contacts of novel and familiar objects. Contrary to other reports of animal models with reduced PV immuno-reactivity, GCLM-KO mice display normal rule learning capacity and perform normally on a spatial recognition task. GCLM-KO mice do, however, show a strong deficit in object-recognition after a 15 minutes retention delay. GBR12909 treatment exerts no additional effect. Conclusions: The results suggest that animals with impaired regulation of brain oxidative stress are impulsive and have reduced behavioural control in novel, unpredictable contexts. Moreover, GSH dysregulation seems to induce a selective attentional or stimulus-encoding deficit: despite intensive object exploration, GCLM-KO mice cannot discriminate between novel and familiar objects. In conclusion, the present data indicate that GSH dysregulation may contribute to the manifestation of behavioural and cognitive anomalies that are associated with schizophrenia.

Affymetrix Whole-Transcript Human Gene 1.0 ST array is highly concordant with standard 3' expression arrays.

The recently released Affymetrix Human Gene 1.0 ST array has two major differences compared with standard 3' based arrays: (i) it interrogates the entire mRNA transcript, and (ii) it uses DNA targets. To assess the impact of these differences on array performance, we performed a series of comparative hybridizations between the Human Gene 1.0 ST and the Affymetrix HG-U133 Plus 2.0 and the Illumina HumanRef-8 BeadChip arrays. Additionally, both RNA and DNA targets were hybridized on HG-U133 Plus 2.0 arrays. The results show that the overall reproducibility of the Gene 1.0 ST array is best. When looking only at the high intensity probes, the reproducibility of the Gene 1.0 ST array and the Illumina BeadChip array is equally good. Concordance of array results was assessed using different inter-platform mappings. Agreements are best between the two labeling protocols using HG-U133 Plus 2.0 array. The Gene 1.0 ST array is most concordant with the HG-U133 array hybridized with cDNA targets. This may reflect the impact of the target type. Overall, the high degree of correspondence provides strong evidence for the reliability of the Gene 1.0 ST array.

Lymph node stromal cells in homeostasis and immune response

Summary : Antigen-specific T lymphocytes constantly patrol the body to search for invading pathogens. Given the large external and internal body surfaces that need to be surveyed, a sophisticated strategy is necessary to facilitate encounters between T cells and pathogens. Dendritic cells present at all body surfaces are specialized in capturing pathogens and bringing them to T zones of secondary lymphoid organs, such as the lymph nodes and the spleen. Here, dendritic cells present antigenic fragments and activate the rare antigen-specific T lymphocytes. This induction of an immune response is facilitated in multiple ways by a dense network of poorly characterized stromal cells, termed fibroblastic reticular cells (FRCs). They constitutively produce the chemokines CCL21 and CCL19, which attract naïve T cells and dendritic cells into the T zone. Further, they provide an adhesion scaffold for dendritic cells and a migration scaffold for naïve T cells, allowing efficient screening of dendritic cell by thousands of T cells. FRCs also form a system of microchannels (conduits) that allows rapid transport of antigen or cytokines from the subcapsular sinus to the T zone. We characterized lymph node FRCS by flow cytometry, immunofluorescence microscopy, real time PCR and functional assays and could show that FRCs are a unique type of myofibroblasts which produce the T cell survival factor IL-7. This function was shown to be critically involved in regulating the size of the peripheral T cell pool and further demonstrates the importance of FRCs in maintaining immunocompetence. As we observed that some dendritic cells also express the receptor for IL-7, we expected a similar function of IL-7 in their survival. Surprisingly, we found no role for IL-7 in their survival but in their development. Analysis of hematopoietic precursors suggested that part of the dendritic cell pool develops out of an IL-7 dependent precursor, which maybe shared with lymphocytes. During the induction of an immune response, lymph node homeostasis is drastically altered when the lymph node expands several-fold in size to accommodate many more lymphocytes. Here, we describe that this expansion of the T zone is accompanied by the activation and proliferation of FRCs thereby preserving T zone architecture and function. This expansion of the FRC network is regulated by antigen-independent and -dependent events. It demonstrates the incredible plasticity of this organ allowing clonal expansion of antigen-specific lymphocytes. Résumé : Les lymphocytes T, spécifiques pour un antigène particulier, patrouillent constamment le corps à la recherche de l'invasion de pathogène. A cause des grandes surfaces externes et internes du corps, une stratégie sophistiquée est nécessaire afin de faciliter les rencontres entre les cellules T et les agents pathogènes. Les cellules dendritiques présentes dans toutes les surfaces du corps sont spécialisées dans la capture des agents pathogènes et dans le transport vers les zones T des organes lymphoïdes secondaires, comme les ganglions lymphatiques et la rate. Dans ces organes, les cellules dendritiques présentent les fragments antigéniques et activent les lymphocytes T rares. L'induction de cette réponse immunitaire est facilitée de différentes manières par un réseau dense de cellules strornales mal caractérisé, appelées 'fibroblastic reticular tells' (FRCs). FRCs produisent constitutivement les chimiokines CCL21 et CCL19, qui attirent les lymphocytes T naïfs et les cellules dendritiques vers la zone T. En outre, elles donnent une base d'adhérence pour les cellules dendritiques et elles attirent les cellules T naïves vers les cellules dendritiques. Les FRCs forment des petits canaux (ou conduits) qui permettent le transport rapide d'antigènes solubles ou de cytokines vers la zone T. Nous avons caractérisé les FRCs par cytométrie en flux, immunofluorescence et par PCR en temps réel et nous avons démontré que les FRCs sont un type unique de rnyofibroblastes qui produisent un facteur de survie des cellules T, l'Interleukine-7. Il a été démontré que cette fonction est cruciale afin d'augmenter la taille et la diversité du répertoire de cellules T, et ainsi, maintenir l'immunocompétence. Comme nous avons observé que certaines cellules dendritiques expriment également le récepteur de l'IL-7, nous avons testé une fonction similaire dans leur survie. Étonnamment, nous n'avons pas trouvé de rôle pour l'IL-7 dans leur survie, mais dans leur développement. L'analyse des précurseurs hématopoïétiques a suggéré qu'une fraction des cellules dendritiques se développe à partir des précurseurs dépendants de l'IL-7, qui sont probablement partagés avec les lymphocytes. Au cours de l'induction d'une réponse immunitaire, l'homéostasie du ganglion lymphatique est considérablement modifiée. En effet, sa taille augmente considérablement afin d'accueillir un plus grand nombre de lymphocytes. Nous décrivons ici que cet élargissement de la zone T est accompagné par l'activation et 1a prolifération des FRCs, préservant l'architecture et la fonction de la zone T. Cette expansion du réseau des FRCs est régie par des évènements à la fois dépendants et indépendants de l'antigène. Cela montre l'incroyable plasticité de cet organe qui permet l'expansion clonale des lymphocytes T spécifiques.

Markers of atherosclerosis and of inflammation for prediction of coronary heart disease in older adults

BACKGROUND: Several markers of atherosclerosis and of inflammation have been shown to predict coronary heart disease (CHD) individually. However, the utility of markers of atherosclerosis and of inflammation on prediction of CHD over traditional risk factors has not been well established, especially in the elderly. METHODS: We studied 2202 men and women, aged 70-79, without baseline cardiovascular disease over 6-year follow-up to assess the risk of incident CHD associated with baseline noninvasive measures of atherosclerosis (ankle-arm index [AAI], aortic pulse wave velocity [aPWV]) and inflammatory markers (interleukin-6 [IL-6], C-reactive protein [CRP], tumor necrosis factor-a [TNF-a]). CHD events were studied as either nonfatal myocardial infarction or coronary death ("hard" events), and "hard" events plus hospitalization for angina, or the need for coronary-revascularization procedures (total CHD events). RESULTS: During the 6-year follow-up, 283 participants had CHD events (including 136 "hard" events). IL-6, TNF-a and AAI independently predicted CHD events above Framingham Risk Score (FRS) with hazard ratios [HR] for the highest as compared with the lowest quartile for IL-6 of 1.95 (95%CI: 1.38-2.75, p for trend<0.001), TNF-a of 1.45 (95%CI: 1.04-2.02, p for trend 0.03), of 1.66 (95%CI: 1.19-2.31) for AAI £0.9, as compared to AAI 1.01-1.30. CRP and aPWV were not independently associated with CHD events. Results were similar for "hard" CHD events. Addition of IL-6 and AAI to traditional cardiovascular risk factors yielded the greatest improvement in the prediction of CHD; C-index for "hard"/total CHD events increased from 0.62/0.62 for traditional risk factors to 0.64/0.64 for IL-6 addition, 0.65/0.63 for AAI, and 0.66/0.64 for IL-6 combined with AAI. Being in the highest quartile of IL-6 combined with an AAI £ 0.90 or >1.40 yielded an HR of 2.51 (1.50-4.19) and 4.55 (1.65-12.50) above FRS, respectively. With use of CHD risk categories, risk prediction at 5 years was more accurate in models that included IL-6, AAI or both, with 8.0, 8.3 and 12.1% correctly reclassified respectively. CONCLUSIONS: Among older adults, markers of atherosclerosis and of inflammation, particularly IL-6 and AAI, are independently associated with CHD. However, these markers only modestly improve cardiovascular risk prediction beyond traditional risk factors. Acknowledgments: This study was supported by Contracts NO1-AG-6-2101, NO1-AG-6- 2103, and NO1-AG-6-2106 of the National Institute on Aging. This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging.

Neuroprotection in cerebral ischemia with XG-102, a new peptide inhibitor of JNK

Abstract Stroke or cerebrovascular accident, whose great majority is of ischemic nature, is the third leading cause of mortality and long lasting disability in industrialised countries. Resulting from the loss of blood supply to the brain depriving cerebral tissues of oxygen and glucose, it induces irreversible neuronal damages. Despite the large amount of research carried out into the causes and pathogenic features of cerebral ischemia the progress toward effective treatments has been poor. Apart the clot-busting drug tissue-type plasminogen activator (tPA) as effective therapy for acute stroke (reperfusion by thrombolysis) but limited to a low percentage of patients, there are currently no other approved medical treatments. The need for new therapy strategies is therefore imperative. Neuronal death in cerebral ischemia is among others due to excitotoxic mechanisms very early after stroke onset. One of the main involved molecular pathways leading to excitotoxic cell death is the c-Jun NH2-terminal kinase (JNK) pathway. Several studies have already shown the efficacy of a neuroprotective agent of a new type, a dextrogyre peptide synthesized in the retro inverso form (XG102, formerly D-JNKI1), which is protease-resistant and cell-penetrating and that selectively and strongly blocks the access of JNK to many of its targets. A powerful protection was observed with this compound in several models of ischemia (Borsello et al. 2003;Hirt et al. 2004). This chimeric compound, made up of a 10 amino acid TAT transporter sequence followed by a 20 amino acids JNK binding domain (JBD) sequence from JNK inhibitor protein (JIP) molecule, induced both a major reduction in lesion size and improved functional outcome. Moreover it presents a wide therapeutic window. XG-102 has proved its powerful efficacy in an occlusion model of middle cerebral artery in mice with intracérebroventricular (i.c.v.) injection but in order to be able to consider the development of this drug for human ischemic stroke it was therefore necessary to determine the feasibility of its systemic administration. The studies being the subject of this thesis made it possible to show a successful neuroprotection with XG-102 administered systemically after transient mouse middle cerebral artery occlusion (MCAo). Moreover our data. provided information about the feasibility to combine XG-102 with tPA without detrimental action on cell survival. By combining the benefits from a reperfusion treatment with the effects of a neuroprotective compound, it would represent the advantage of bringing better chances to protect the cerebral tissue. Résumé L'attaque cérébrale ou accident vasculaire cérébral, dont la grande majorité est de nature ischémique, constitue la troisième cause de mortalité et d'infirmité dans les pays industrialisés. Résultant de la perte d'approvisionnement de sang au cerveau privant les tissus cérébraux d'oxygène et de glucose, elle induit des dommages neuronaux irréversibles. En dépit du nombre élevé de recherches effectuées pour caractériser les mécanismes pathogènes de l'ischémie. cérébrale, les progrès vers des traitements efficaces restent pauvres. Excepté l'activateur tissulaire du plasminogène (tPA) dont le rôle est de désagréger les caillots sanguins et employé comme thérapie efficace contre l'attaque cérébrale aiguë (reperfusion par thrombolyse) mais limité à un faible pourcentage de patients, il n'y a actuellement aucun autre traitement médical approuvé. Le besoin de nouvelles stratégies thérapeutiques est par conséquent impératif. La mort neuronale dans l'ischémie cérébrale est entre autres due à des mécanismes excitotoxiques survenant rapidement après le début de l'attaque cérébrale. Une des principales voies moléculaires impliquée conduisant à la mort excitotoxique des cellules est la voie de la c-Jun NH2terminal kinase (JNK). Plusieurs études ont déjà montré l'efficacité d'un agent neuroprotecteur d'un nouveau type, un peptide dextrogyre synthétisé sous la forme retro inverso (XG-102, précédemment D-JNKI1) résistant aux protéases, capable de pénétrer dans les cellules et de bloquer sélectivement et fortement l'accès de JNK à plusieurs de ses cibles. Une puissante protection a été observée avec ce composé dans plusieurs modèles d'ischémie (Borsello et al. 2003;Hirt et al. 2004). Ce composé chimérique, construit à partir d'une séquence TAT de 10 acides aminés suivie par une séquence de 20 acides aminés d'un domaine liant JNK (JBD) issu de la molécule JNK protéine inhibitrice. (JIP), induit à la fois une réduction importante de la taille de lésion et un comportement fonctionnel amélioré. De plus il présente une fenêtre thérapeutique étendue. XG-102 a prouvé sa puissante efficacité dans un modèle d'occlusion de l'artère cérébrale moyenne chez la souris avec injection intracerebroventriculaire (i.c.v.) mais afin de pouvoir envisager le développement de ce composé pour l'attaque cérébrale chez l'homme, il était donc nécessaire de déterminer la faisabilité de son administration systémique. Les études faisant l'objet de cette thèse ont permis de montrer une neuroprotection importante avec XG-102 administré de façon systémique après l'occlusion transitoire de l'artère cérébrale moyenne chez la souris (MCAo). De plus nos données ont fourni des informations quant à la faisabilité de combiner XG-102 et tPA, démontrant une protection efficace par XG-102 malgré l'action nuisible du tPA sur la survie des cellules. En combinant les bénéfices de la reperfusion avec les effets d'un composé neurooprotecteur, cela représenterait l'avantage d'apporter des meilleures chances de protéger le tissu cérébral.

Gac/Rsm signal transduction pathway of gamma-proteobacteria: from RNA recognition to regulation of social behaviour.

In many gamma-proteobacteria, the conserved GacS/GacA (BarA/UvrY) two-component system positively controls the expression of one to five genes specifying small RNAs (sRNAs) that are characterized by repeated unpaired GGA motifs but otherwise appear to belong to several independent families. The GGA motifs are essential for binding small, dimeric RNA-binding proteins of a single conserved family designated RsmA (CsrA). These proteins, which also occur in bacterial species outside the gamma-proteobacteria, act as translational repressors of certain mRNAs when these contain an RsmA/CsrA binding site at or near the Shine-Dalgarno sequence plus additional binding sites located in the 5' untranslated leader mRNA. Recent structural data have established that the RsmA-like protein RsmE of Pseudomonas fluorescens makes specific contacts with an RNA consensus sequence 5'-(A)/(U)CANGGANG(U)/(A)-3' (where N is any nucleotide). Interaction with an RsmA/CsrA protein promotes the formation of a short stem supporting an ANGGAN loop. This conformation hinders access of 30S ribosomal subunits and hence translation initiation. The output of the Gac/Rsm cascade varies widely in different bacterial species and typically involves management of carbon storage and expression of virulence or biocontrol factors. Unidentified signal molecules co-ordinate the activity of the Gac/Rsm cascade in a cell population density-dependent manner.